Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pachner, A. R.
Right arrow Articles by Deisenhammer, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pachner, A. R.
Right arrow Articles by Deisenhammer, F.
NEUROLOGY 2003;61:S24-S26
© 2003 American Academy of Neurology

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Measurement of MxA mRNA or protein as a biomarker of IFNß bioactivity

Detection of antibody-mediated decreased bioactivity (ADB)

Andrew R. Pachner, MD, Antonio Bertolotto, MD and Florian Deisenhammer, MD

From the Department of Neurology and Neurosciences (Dr. Pachner), UMDNJ-New Jersey Medical School, Newark, NJ; S.S.D. CReSM & Neurobiologia Clinica (Dr. Bertolotto), Orbassano, (TO), Italy; University of Innsbruck (Dr. Deisenhammer), Innsbruck, Austria.

Address correspondence and reprint requests to Dr. Andrew R. Pachner, Department of Neurology and Neurosciences, UMDNJ-New Jersey Medical School, 185 S. Orange Avenue, Newark, NJ.

Myxovirus A (MxA) is a protein that is specifically induced by treatment with type I cytokines and has proven to be a reliable biomarker of interferon-ß (IFNß) bioactivity. IFNß-induced MxA can be measured as either protein or mRNA in the blood of IFNß-treated patients with MS. In patients with MS who are treated with IFNß, loss of the MxA response is caused by high levels of anti-IFNß antibodies and is a sensitive marker of lost bioactivity.




This article has been cited by other articles:


Home page
 BrainHome page
M. Krumbholz, H. Faber, F. Steinmeyer, L.-A. Hoffmann, T. Kumpfel, H. Pellkofer, T. Derfuss, C. Ionescu, M. Starck, C. Hafner, et al.
Interferon-{beta} increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity
Brain, June 1, 2008; 131(6): 1455 - 1463.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
N. Somani, M. Martinka, R. I. Crawford, J. P. Dutz, and J. K. Rivers
Treatment of Atypical Nevi With Imiquimod 5% Cream
Arch Dermatol, March 1, 2007; 143(3): 379 - 385.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al.
Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations
Arch Neurol, October 1, 2005; 62(10): 1519 - 1530.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.